Market News AIOpen the app

Eli Lilly will buy Calytrix Bio for as much as $1.5 billion while new data comes out at ObesityWeek.

DealRead the original at Benzinga
Good for LLY

Lilly agreed to pay Calytrix owners cash upfront and more if later study and approval goals are met, and reported benefits across several drug studies. Calytrix's drug is still being tested, but the wider set of results supports Lilly's future treatments.

LLY · Eli Lilly and Company

AI read · Good for LLY

The AI's read

Calytrix's drug targets a specific blood disease, but it is still being tested. Lilly also reported weight and health improvements across several drug studies. Those results support Lilly's future treatment options, though the deal commits cash and some payments depend on later milestones.

Get alerts for LLY

Follow Eli Lilly and Company (LLY) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LLY
Free on the App Store and Google Play, or on the web.